文献速递血栓与止血

以治疗药物监测指导儿童免疫性血小板减少症中艾曲泊帕个体化应用的探索性研究

Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring.
PubMed 文献 · Br J Haematol · 2024-09-02

这项单中心、前瞻性、观察性研究纳入39例儿童免疫性血小板减少症患者,依据艾曲泊帕浓度调整剂量并分为维持组、停药组和增量组,比较浓度等数据以探索其在个体化治疗中的价值。浓度可作为儿童免疫性血小板减少症中艾曲泊帕个体化治疗的参考指标。

要点

  • 39例患儿中维持组23例、停药组3例、增量组13例。
  • 3例因不良反应停药,显著高于维持组(t=3.606,p=0.001)。
  • 增量后2个月达完全缓解和缓解的人数分别增加2例和3例,中位血小板计数显著升高(Z=-2.411,p=0.016)。

核心结论

  • 浓度可作为儿童免疫性血小板减少症中艾曲泊帕个体化治疗的参考指标。

研究设计与样本

  • 单中心、前瞻性、观察性研究,纳入39例儿童免疫性血小板减少症患者。
  • 依据浓度调整艾曲泊帕剂量,分为维持组(23例)、停药组(3例)和增量组(13例),比较浓度及其他数据。

主要发现

  • 3例因不良反应停用艾曲泊帕,显著高于维持组(t=3.606,p=0.001)。
  • 13例因疗效不佳增加剂量,其浓度和血小板计数显著低于维持组(t=2.461,p=0.019;t=4.633,p<0.001)。
  • 增量后2个月,达到完全缓解和缓解的患者数分别增加2例和3例,中位血小板计数显著升高(Z=-2.411,p=0.016)。

临床怎么用

  • 作者认为浓度可作为儿童免疫性血小板减少症中艾曲泊帕个体化治疗的参考指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are variations in individual eltrombopag concentrations that may impact efficacy and adverse drug reactions (ADRs) in paediatric immune thrombocytopenia (ITP). To solve this problem, we tailored the eltrombopag dosage refer to concentration, then followed up to assess concentration value in paediatric ITP. This is a single-centre, prospective, observational study. The eltrombopag dosage was adjusted, and children were divided into three groups: the maintenance, discontinuation, and increase groups. Concentration and other data were compared to explore concentration value in guiding the individualized treatment of paediatric ITP. Thirty-nine patients were enrolled, including 23 in the maintenance group, 3 in the discontinued group and 13 in the increase group. 3 patients discontinued eltrombopag due to ADRs, which was significantly higher than patients in the maintenance group (t = 3.606, p = 0.001). In all, 13 patients increased their dosage due to poor response, whose concentration and platelet count were significantly lower than patients in the maintenance group (t = 2.461, p = 0.019; t = 4.633, p < 0.001). Two months after the increase, the number of patients reaching CR and R respectively increased by 2 and 3, while the median platelet count was significantly raised (Z = -2.411, p = 0.016). Concentration could be used as a reference index for the individualized treatment of eltrombopag in paediatric ITP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dong S, Wang Z, Wang N, et al. Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring. Br J Haematol. 2024. PMID: 39223899. doi:10.1111/bjh.19735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。